Analyst Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at $32.00. Thomas Shrader’s rating is based on Denali ...

Chardan Capital analyst Daniil Gataulin maintained a Hold rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target of $3.00. The company’s shares closed last Friday ...

German electronic music pioneers Kraftwerk have announced they will celebrate the 50th anniversary of their iconic Autobahn album with reissues on three different formats through Parlophone Records on ...

Cardiol Therapeutics President and CEO, David ElsleyNEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics ...

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has closed its previously announced registered direct ...

(Image Credits: Pixabay) Immuneel Therapeutics on Monday launched Qartemi, a CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL). According to the company’s statement, it is ...

This page features the latest news about the Century Therapeutics stock. Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B ...

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP ...

Our round-up of recent biotech financings features a strong first round for City Therapeutics, a new RNAi venture led by biotech doyen John Maraganore, and additional cash for Purespring ...